Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
| 0.4026 | |
| 0.4178 | |
| - | |
| 0.43 | |
| 0.3901 | |
| 0.1866-1.58 | |
| 12 415 K | |
| 29 793 K | |
| 560 | |
| -0.006 | |
| 2.131 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
If you’ve read all the warnings and still want to jump into some of the top penny stocks to buy, focus on the key fundamentals. That includes its earnings numbers, business models, product pipeline...
In this piece, we will take a look at the 11 best ASX stocks to buy now. If you want to skip our introduction to the Australian stock market, then you can take a look at the 5 Best ASX Stocks To Buy N...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
